Antitumor activity of silver nanoparticles in Dalton's lymphoma ascites tumor model.
Nanomedicine concerns the use of precision-engineered nanomaterials to develop novel therapeutic and diagnostic modalities for human use. The present study demonstrates the efficacy of biologically synthesized silver nanoparticles (AgNPs) as an antitumor agent using Dalton's lymphoma ascites (DLA) cell lines in vitro and in vivo. The AgNPs showed dose- dependent cytotoxicity against DLA cells through activation of the caspase 3 enzyme, leading to induction of apoptosis which was further confirmed through resulting nuclear fragmentation. Acute toxicity, ie, convulsions, hyperactivity and chronic toxicity such as increased body weight and abnormal hematologic parameters did not occur. AgNPs significantly increased the survival time in the tumor mouse model by about 50% in comparison with tumor controls. AgNPs also decreased the volume of ascitic fluid in tumor-bearing mice by 65%, thereby returning body weight to normal. Elevated white blood cell and platelet counts in ascitic fluid from the tumor-bearing mice were brought to near-normal range. Histopathologic analysis of ascitic fluid showed a reduction in DLA cell count in tumor-bearing mice treated with AgNPs. These findings confirm the antitumor properties of AgNPs, and suggest that they may be a cost-effective alternative in the treatment of cancer and angiogenesis-related disorders.
Department of Biotechnology, Division of Molecular and Cellular Biology, Kalasalingam University, Tamilnadu, India.
Muthu Irulappan
MI
Sriram
Selvaraj Barath Mani
SB
Kanth
Kalimuthu
K
Kalishwaralal
Sangiliyandi
S
Gurunathan
D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D017209:Apoptosis / Q000187:drug effects; D001201:Ascites / Q000188:drug therapy / Q000201:enzymology / Q000473:pathology; D053148:Caspase 3 / Q000378:metabolism; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects; D005260:Female; D006801:Humans; D066298:In Vitro Techniques; D008223:Lymphoma / Q000188:drug therapy* / Q000201:enzymology / Q000473:pathology; D053768:Metal Nanoparticles / Q000008:administration & dosage* / Q000627:therapeutic use; D051379:Mice; D050997:Nanomedicine; D012834:Silver / Q000008:administration & dosage* / Q000627:therapeutic use
D000970:Antineoplastic Agents; D012834:Silver; C505409:Casp3 protein, mouse; D053148:Caspase 3